These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19508488)

  • 21. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
    Puig L; Roé E; García-Navarro X; Corella F; Alomar A
    Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biological treatment of psoriasis and psoriatic arthritis].
    Kragballe K; Deleuran B
    Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases.
    Antonucci A; Bardazzi F; Balestri R; Patrizi A
    J Dermatolog Treat; 2009; 20(1):61-2. PubMed ID: 18618361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psoriasiform keratosis.
    Walsh SN; Hurt MA; Santa Cruz DJ
    Am J Dermatopathol; 2007 Apr; 29(2):137-40. PubMed ID: 17414434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological findings of canine seborrhoeic keratosis with comparison to pigmented viral plaques.
    Bradley CW; Luff JA; Mauldin EA
    Vet Dermatol; 2013 Aug; 24(4):432-8, e95. PubMed ID: 23738925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
    Wozel G; Vitéz L; Meurer M
    Acta Dermatovenerol Alp Pannonica Adriat; 2008 Sep; 17(3):133-6. PubMed ID: 18853077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unusual clinical manifestation of seborrheic keratosis on the scalp successfully treated with topical trichloroacetic acid: an atypical case report.
    Komalasari DN; Djawad K; Nurdin AR; Paturusi II
    Pan Afr Med J; 2020; 37():98. PubMed ID: 33425131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rebound of psoriasis during treatment with efalizumab.
    Golda N; Benham SM; Koo J
    J Drugs Dermatol; 2006 Jan; 5(1):63-5. PubMed ID: 16468294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
    Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
    Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meyerson's phenomenon around a seborrhoeic keratosis.
    Dawn G; Burden AD
    Clin Exp Dermatol; 2002 Jan; 27(1):73. PubMed ID: 11952680
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.
    Tsai TF; Liu MT; Liao YH; Licu D
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):345-52. PubMed ID: 18005021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efalizumab-induced inflammatory polyarthritis: what are the implications?
    Lyman J; Serebro L
    South Med J; 2010 Apr; 103(4):357-60. PubMed ID: 20224509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
    Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
    Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Leser-Trélat sign is associated with nasopharyngeal carcinoma: case report and review of cases reported in China.
    Li M; Yang LJ; Zhu XH; Zhang YS; Sun H; Jiang PD; Zhang RR; Tang W; Cai Y
    Clin Exp Dermatol; 2009 Jan; 34(1):52-4. PubMed ID: 19076792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy.
    Kircik LH; Liu C; Goffe BS
    J Drugs Dermatol; 2008 Oct; 7(10):947-52. PubMed ID: 19112758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
    Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
    Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.
    Myers WA; Najarian D; Gottlieb AB
    J Dermatolog Treat; 2006; 17(6):353-4. PubMed ID: 17853308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
    Papp KA; Toth D; Rosoph L
    BMC Dermatol; 2006 Oct; 6():9. PubMed ID: 17067371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.